in guideline Pneumococcal 13-Valent Conjugate Vaccine Sufficient http://bioportal.bioontology.org/ontologies/NCIT/?p=classes&conceptid=http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C97121 SCDO:0000910 Prevnar 13 NCIT:C97121 A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease. The pneumococcal 13-valent conjugate vaccine contains capsular antigen polysaccharides derived from the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F that are individually conjugated to a nontoxic diphtheria cross-reactive material (CRM) carrier protein (CRM197). Upon vaccination, pneumococcal 13-valent conjugate vaccine induces active immunization against 13 different serotypes of S. pneumoniae and protects against pneumococcal disease. PCV 13 PCV13 Vaccine Conjugate Pneumococcal Vaccine Management of Sickle Cell Disease - The United Republic of Tanzania Sickle Cell Disease: The Clinical Care Guidelines of the Sickle Cell Unit Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada Sickle Cell Disease in Children, Standards and Guidelines for Clinic Care Evidence-Based Management of Sickle Cell Disease